

U.S. Application No.  
Unknown

International Application No.  
PCT/EP00/02699

10/019513  
JC18 Rec'd PCT/PTO 16 OCT 2001  
Attorney Docket No.  
WWELL52.001APC

Date: October 16, 2001

Page 1

**TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 USC 371**

International Application No.: PCT/EP00/02699  
International Filing Date: March 28, 2000  
Priority Date Claimed: April 16, 1999  
Title of Invention: PEPTIDE FOR TRIGGERING AN IMMUNE REACTION AGAINST  
TUMOR CELLS  
Applicant(s) for DO/EO/US: Peter Brossart, Stefan Stevanovic, Wolfram Brugger, Lothar Kanz, and Hans  
Georg Rammensee

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. (X) This is a **FIRST** submission of items concerning a filing under 35 USC 371.
2. (X) This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).
3. (X) A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
4. (X) A copy of the International Application as filed (35 USC 371(c)(2))
  - a) () is transmitted herewith (required only if not transmitted by the International Bureau).
  - b) (X) has been transmitted by the International Bureau.
  - c) () a copy of Form PCT/1B/308 is enclosed.
  - d) () is not required, as the application was filed in the United States Receiving Office (RO/US).
5. (X) A translation of the International Application into English (35 USC 371(c)(2)).
6. (X) Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3))
  - a) () are transmitted herewith (required only if not transmitted by the International Bureau).
  - b) () have been transmitted by the International Bureau.
  - c) () have not been made; however, the time limit for making such amendments has NOT expired.
  - d) (X) have not been made and will not be made.
7. (X) A copy of the International Preliminary Examination Report with any annexes thereto, such as any amendments made under PCT Article 34. No translation of the annex is provided, as the claims to be examined in the U.S. national phase are set forth in the enclosed Preliminary Amendment.
8. (X) An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
9. (X) A FIRST preliminary amendment.
10. (X) International Application as published.
11. (X) A return prepaid postcard.

U.S. Application No.  
Unknown

International Application No.  
PCT/EP00/02699

Date: October 16, 2001

Page 2


12. (X) Diskette with sequence listing .  
13. (X) Sequence Submission Statement.  
14. (X) The following fees are submitted:

				FEES
BASIC FEE				\$890
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	25 - 20 =	5 ×	\$18	\$90
Independent Claims	6 - 3 =	3 ×	\$84	\$252
Multiple dependent claims(s) (if applicable)			\$280	\$0
TOTAL OF ABOVE CALCULATIONS				\$1232
TOTAL FEES ENCLOSED				\$1232

15. (X) The fee for later submission of the signed oath or declaration set forth in 37 CFR 1.492(e) will be paid upon submission of the declaration.  
16. (X) A check in the amount of \$1232 to cover the above fees is enclosed.  
17. (X) The Commissioner is hereby authorized to charge only those additional fees which may be required, now or in the future, to avoid abandonment of the application, or credit any overpayment to Deposit Account No. 11-1410.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

  
Daniel E. Altman  
Reg. No. 34,115  
Customer No. 20,995

**Knobbe Martens Olson & Bear LLP**

*Intellectual Property Law*

620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
Tel 949-760-0404  
Fax 949-760-9502  
www.kmob.com

Assistant Commissioner for Patents  
Washington, D.C. 20231


**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

**Attorney Docket No. :** WWELL52.001APC  
**Applicant(s) :** Brossart, et al.  
**For :** PEPTIDE FOR TRIGGERING AN IMMUNE  
REACTION AGAINST TUMOR CELLS  
**Attorney :** Daniel E. Altman  
**"Express Mail"**  
**Mailing Label No. :** EL561649447US  
**Date of Deposit :** October 16, 2001

I hereby certify that the accompanying

Transmittal; Demand; Copy of International Application in 30 pages; English Translation of the Application; Preliminary Amendment in 5 pages; International Preliminary Examination Report; International Search Report; Information Disclosure Statement, PTO Form 1449 with 5 references; Diskette with sequence listing; Sequence submission statement; Check for Filing Fee; Return Prepaid Postcard

are being deposited with the United States Postal Service "Express Mail Post Office To Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Sylvia Gaston

O:\DOCS\CMS\CMS-1831.DOC:vb  
101201

100107019513

JG13 Rec'd PGT/PTO 16 OCT 2001

WWELL52.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Brossert, et al. )  
)  
Appl. No. : Unknown )  
)  
Filed : Herewith )  
)  
For : PEPTIDE FOR TRIGGERING )  
AN IMMUNE REACTION )  
AGAINST TUMOR CELLS )  
)  
Examiner : Unknown )

SEQUENCE SUBMISSION STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

A copy of the Sequence Listing in computer readable form as required by 37 C.F.R. § 1.821(e) is submitted herewith.

As required by 37 C.F.R. § 1.821(f), I hereby declare that the information recorded on the enclosed disk is identical to the printed Sequence Listing in the application filed herewith.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 16 Oct. 2001

By: Daniel Altman  
Daniel E. Altman  
Registration No. 34,115  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660

O:\DOCS\CMSCMS-1839.DOC 101601

WWELL52.001APC

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant	:	Brossart, et al.	)	Group Art Unit Unknown
			)	
Int'l Appl. No. :		PCT/EP00/2699	)	
			)	
Int'l Filing			)	
Date	:	March 28, 2000	)	
			)	
For	:	PEPTIDE FROM ANTIGEN	)	
		MUC-1 FOR TRIGGERING	)	
		AN IMMUNE RESPONSE TO	)	
		TUMOR CELLS	)	
			)	
Examiner	:	Unknown		

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Prior to examination on the merits, please amend the above-captioned patent application as follows:

**IN THE SPECIFICATION:**

On Page 1 following the Title of the Invention and before the first paragraph, please insert the following:

**CROSS REFERENCE TO RELATED APPLICATIONS**

This application is the U.S. National Phase under 35 U.S.C. § 371 of International Application No. PCT/EP00/02699, which was published in German and claims priority to German patent application number 19917195.5, filed April 16, 1999. This German patent application is herein incorporated by reference.

Int'l Appl. No. : PCT/EP00/2699  
Int'l Filing Date : March 28, 2000

**IN THE CLAIMS:**

**Please cancel Claims 2-10.**

**Please amend Claim 1, as follows:**

1. An isolated peptide comprising SEQ ID NO: 1:  
Ser Thr Ala Pro Pro Val His Asn Val.

**Please add the following claims:**

11. An isolated peptide having an amino acid sequence from a signal peptide encoded by the MUC-1 gene.

12. The peptide of Claim 11, comprising SEQ ID NO:2:  
Leu Leu Leu Leu Thr Val Leu Thr Val.

13. A nucleic acid having a sequence coding for a peptide selected from the group consisting of SEQ ID NO:1, an amino acid sequence from a signal peptide encoded by the MUC-1 gene, and SEQ ID NO:2.

14. A vector comprising the nucleic acid of Claim 13, wherein said vector is capable of expression in a cell.

15. A pharmaceutical composition comprising a peptide selected from the group consisting of SEQ ID NO:1, an amino acid sequence from a signal peptide encoded by the MUC-1 gene, and SEQ ID NO:2.

16. A pharmaceutical composition comprising the nucleic acid of Claim 13.

17. A method for gene therapy, comprising the step of administering the nucleic acid of Claim 13 to a person in need of such therapy.

18. A method for gene therapy, comprising the step of administering the vector of Claim 14 to a person in need of such therapy.

19. A cell comprising the nucleic acid of Claim 13.

20. A cell comprising the vector of Claim 14.

21. A method for tumor therapy, comprising the step of triggering an immune reaction by administering to a subject a peptide selected from the group consisting of SEQ ID NO:1, an amino acid sequence from a signal peptide encoded by the MUC-1 gene, and SEQ ID NO:2.

Int'l Appl. No. : PCT/EP00/2699  
Int'l Filing Date : March 28, 2000

22. A method for tumor therapy, comprising the step of triggering an immune reaction in a subject by administering to said subject the nucleic acid of Claim 13.

23. A method of tumor therapy, comprising the step of triggering an immune reaction in a subject by administering to said subject the vector of Claim 14.

24. A method for prophylactic treatment with respect to the development of a tumor, comprising the step of triggering an immune reaction with a peptide of the group comprising SEQ ID NO:1, an amino acid sequence from a signal peptide encoded by the MUC-1 gene, and SEQ ID NO:2.

25. A method for prophylactic treatment with respect to the development of a tumor, comprising the step of triggering an immune reaction in a subject by administering to said subject the nucleic acid of Claim 13.

26. A method for prophylactic treatment with respect to development of a tumor, comprising the step of triggering an immune reaction in a subject by administering to said subject the vector of Claim 14.

27. The method of Claim 21, wherein said peptide is incubated together with antigen-presenting cells and wherein said antigen-presenting cells are then administered to the organism from which the antigen-presenting cells or precursor cells of the same were derived.

28. The method of Claim 22, wherein said nucleic acid is incubated together with antigen-presenting cells and wherein said antigen-presenting cells are then administered to the organism from which the antigen-presenting cells or precursor cells of the same were derived.

29. The method of Claim 24, wherein said peptide is incubated together with antigen-presenting cells and wherein said antigen-presenting cells are then administered to an organism from which the antigen-presenting cells or precursor cells of the same were derived.

30. The method of Claim 25, wherein said nucleic acids is incubated together with antigen-presenting cells and wherein said antigen-presenting cells are then administered to the organism from which the antigen-presenting cells or precursor cells of the same were derived.

31. The method of Claim 27, wherein said antigen-presenting cells are dendritic cells.

32. The method of Claim 28, wherein said antigen-presenting cells are dendritic cells.

33. The method of Claim 29, wherein said antigen-presenting cells are dendritic cells.

34. The method of Claim 30, wherein said antigen-presenting cells are dendritic cells.

#### REMARKS

Int'l Appl. No. : PCT/EP00/2699  
Int'l Filing Date : March 28, 2000

Claim 1 was amended, Claims 2-10 were cancelled, and Claims 11-34 were added to more clearly claim the invention and place them in accordance with conventional practices of the United States Patent and Trademark Office. No new matter has been added. Changes to the claims can be seen on a separate page entitled VERSION WITH MARKINGS TO SHOW CHANGES MADE following the signature page. Deletions are in **[bold and brackets]**, and insertions are underlined.

# Conclusion

Should any questions exist which would delay prosecution of the application filed herewith, the Examiner is respectfully invited to contact the under-signed attorney at the telephone number below.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 16 Oct. 2001

By: Daniel Altman  
Daniel E. Altman  
Registration No. 34,115  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(949) 721-2875

O:\DOCS\CMS\CMS-1820.DOC  
101001



Int'l Appl. No. : PCT/EP00/2699  
Int'l Filing Date : March 28, 2000

VERSION WITH MARKINGS TO SHOW CHANGES MADE  
Deletions are in **[bold and brackets]**, and insertions are underlined.

IN THE SPECIFICATION:

On Page 1 following the Title of the Invention and before the first paragraph, please insert the following:

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a US National Phase application of the International Application No. PCT/EP00/02699, published in German, which claims priority to Germany patent application number 19917195.5, filed April 16, 1999, which are herein incorporated by reference.

IN THE CLAIMS:

**Please cancel Claims 2-10.**

**Please amend Claim 1, as follows:**

1. An isolated peptide[ **that is derived from the MUC-1 gene and by which a HLA-A2-restricted immune reaction against tumor cells can be triggered, characterized in that it comprises the sequence]** comprising SEQ ID NO: 1:

Ser Thr Ala Pro Pro Val His Asn Val[,

**and/or a sequence that is derived from the signal peptide, in particular the sequence** SEQ ID NO: 2:

Leu Leu Leu Leu Thr Val Leu Thr Val,

**and/or**

**a modified form of the sequence SEQ ID NO:1 and/or of the sequence SEQ ID NO:2].**

Int'l Appl. No. : PCT/EP00/2699  
Int'l Filing Date : March 28, 2000

VERSION WITH MARKINGS TO SHOW CHANGES MADE  
Deletions are in **[bold and brackets]**, and insertions are underlined.

IN THE SPECIFICATION:

On Page 1 following the Title of the Invention and before the first paragraph, please insert the following:

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a US National Phase application of the International Application No. PCT/EP00/02699, published in German, which claims priority to Germany patent application number 19917195.5, filed April 16, 1999, which are herein incorporated by reference.

IN THE CLAIMS:

**Please cancel Claims 2-10.**

**Please amend Claim 1, as follows:**

1. An isolated peptide[ **that is derived from the MUC-1 gene and by which a HLA-A2-restricted immune reaction against tumor cells can be triggered, characterized in that it comprises the sequence**] comprising SEQ ID NO: 1:

Ser Thr Ala Pro Pro Val His Asn Val],

**and/or a sequence that is derived from the signal peptide, in particular the sequence SEQ ID NO: 2:**

**Leu Leu Leu Leu Thr Val Leu Thr Val,**

**and/or**

**a modified form of the sequence SEQ ID NO:1 and/or of the sequence SEQ ID NO:2].**

WELLS. COI APC

PATENT

10/019513

JC13 Rec'd PCT/PTO 16 OCT 2001

Peptide for triggering an immune reaction against tumor cells

The present invention relates to a peptide that is derived from the MUC-1 gene, by which peptide a HLA-A2-restricted immune reaction against tumor cells can be triggered.

In an abstract to a lecture held on the 40. annual meeting of the American Society of Hematology, 1998, Brossart et al. show the possibility of deriving such a peptide from the MUC-1 gene, however, without mentioning the sequence of a peptide they tested or the localization of the sequence of a peptide that is not derived from the tandem repeat range of MUC-1.

Peptides for triggering an immune reaction against tumor cells are mentioned, for example, also in the publication by Finn, O.J., et al., (1995) "MUC-1 Epithelial Tumor Mucin-Based Immu-

WELL52.001APC

10019513 PATENT

10/019513

JC13 Rec'd PCT/PTO 16 OCT 2001

Peptide for triggering an immune reaction against tumor cells

The present invention relates to a peptide that is derived from the MUC-1 gene, by which peptide a HLA-A2-restricted immune reaction against tumor cells can be triggered.

In an abstract to a lecture held on the 40. annual meeting of the American Society of Hematology, 1998, Brossart et al. show the possibility of deriving such a peptide from the MUC-1 gene, however, without mentioning the sequence of a peptide they tested or the localization of the sequence of a peptide that is not derived from the tandem repeat range of MUC-1.

Peptides for triggering an immune reaction against tumor cells are mentioned, for example, also in the publication by Finn, O.J., et al., (1995) "MUC-1 Epithelial Tumor Mucin-Based Immu-

nity and Cancer Vaccines", Immunol Rev 145, pages 61-89, but without mentioning sequence information either.

By an immune reaction, for example the destruction of cells by such T cells that are also designated as cytotoxic T cells due to their ability to kill other cells is to be understood. In order to trigger such an immune reaction by cytotoxic T cells, foreign proteins e.g. as a result of a virus infection must be presented to the T cells by a MHC molecule on the cell surface.

These MHC molecules are peptide receptors which usually bind peptides within the cell in order to transport them to the cell surface, where the complex of peptide and MHC molecule can be recognized by T cells. In normal cells, the peptides bound by MHC molecules are derived from the usual cell-owned proteins. During their differentiation in an organism, T cells become tolerant against complexes of own peptides having own MHC molecules. Thus, each new peptide which comes up later, e.g. a peptide which is produced by a cell because of the infection with a virus, can be recognized by T cells.

There are two classes of MHC molecules, whereas those interacting with cytotoxic T cells belong to class I. Classic human class I molecules are HLA-A, B and C, wherein HLA-A2 represents a subclass of the HLA-A molecules.

If the accomplishment of an immune reaction is dependent on the existence of a certain MHC molecule, for example HLA-A2, this is said to be an MHC-restricted, e.g. a HLA-A2-restricted immune reaction. There are also sporadic T cell reactions which

take place independently of MHC molecules. These are said to be MHC-unrestricted immune reactions.

In the publication by Finn et al. mentioned at the outset, for the treatment of a tumor patient it was suggested to trigger such a MHC-unrestricted immune reaction against a glycoprotein that is coded by the gene MUC-1 and exists on the surface of cells. The objective is herein to generate an effective immune response with a life-long immunity.

The protein coded by the gene MUC-1, which protein is also called MUC-1, is in most cases polarizedly expressed by normal epithelial cells such that it is normally not accessible for the immune system, like e.g. in the bowel, where it is expressed on the apical side of the epithelial cells, i.e. projecting into the bowel lumen.

However, MUC-1 is not polarizedly expressed on tumor cells, but covers all of the cell. The level of the expression is higher for tumor cells than for normal cells, but for tumor cells the molecules are not completely glycosylated, i.e. the side chains of saccharine molecules comprise a shortened structure with respect to MUC-1 that is produced by healthy cells. The incomplete glycosylation results in epitopes on the protein portion of MUC-1, which epitopes usually exist masked by saccharine side chains and are accessible on tumor cells for the immune system. Thus, the immune system can distinguish between this underglycosylated MUC-1 and the normal not underglycosylated MUC-1.

Beside the side chains made of saccharine molecules, another essential structure feature are the so-called tandem repeats. These are sequences of 20 amino acid residues which are each repeated in an identical or similar manner approximately 20 to 125 times in the MUC-1 molecule.

For triggering an effective immune reaction by T cells, co-stimulators are required, whereto do belong in particular the so-called dendritic cells which take up proteins presented from outside and can present them after their processing to peptides so that cytotoxic T cells can be activated thereby. Therefore, Finn et al. suggest to inject synthetic peptides which represent the MUC-1 tandem repeats, together with an adjuvans that attracts dendritic cells. An adjuvans is a substance which, when injected together with a substance against which an immune reaction is to be triggered, strengthens the response of the immune system to this substance in an unspecified manner. By such a vaccination, an MHC-unrestricted T cell reaction against the tandem repeats shall be obtained. It is even suggested to replace amino acids which can mediate a MHC-class-I-binding in the synthetic peptides by others so that no MHC-restricted T cells can arise by a presentation of the peptides by MHC class I molecules.

On the one hand, the problem of a possible autoimmunity can be reduced by avoiding an MHC-restricted immune response, on the other hand, the lower efficiency of an MHC-unrestricted immune response in comparison to an MHC-restricted one is a great disadvantage. Thus, the chances are also lower to make a tumor to disappear by means of an MHC-unrestricted immune response than by means of an MHC-restricted immune response.

For this reason, on the occasion of the presentation mentioned at the outset, the inventors of the present application have suggested to trigger a MHC-restricted immune response against MUC-1 expressing cells. They report that to this end the known MUC-1 amino acid sequence has been searched for HLA-A2 binding motives by means of a computer analysis. Peptides with a high binding probability were identified, synthesized and examined with respect to the regard whether they can induce cytotoxic T cells in vitro with the help of dendritic cells. The cytotoxic T cells created in that way developed an antigen-specific HLA-A2-restricted cytotoxic activity against these target cells that had been incubated before with the respective peptide by which the cytotoxic T cells were activated, or against MUC-1 expressing tumor cells.

In view of the above, it is an object of the present invention to provide at least one amino acid sequence for such a peptide for triggering an immune reaction against tumor cells.

This object is achieved according to the invention by the peptide comprising the sequence SEQ ID NO: 1 and/or a sequence that is derived from the signal peptide, in particular the sequence SEQ ID NO: 2 from the enclosed sequence listing, and/or a modified form of the sequence SEQ ID NO: 1 and/or of the sequence SEQ ID NO: 2.

The object underlying the invention is in that way completely achieved.

By means of the peptide according to the invention, cytotoxic T cells can be generated which develop an antigen-specific MHC-



restricted cytotoxic activity against MUC-1 expressing tumor cells and which destroy the latter.

Thus, this peptide offers the possibility of an effective tumor therapy, in which the suppression of an immune reaction against tumor cells often observed in tumor patients can be reversed.

Peptide SEQ ID NO: 1 is a nonapeptide that is derived from the amino acid sequence of a tandem repeat of MUC-1 and that distinguishes from another peptide that has been described earlier, amongst others by two amino acids, the one of which allows a binding of the peptide to the HLA-A2 molecule.

As can be seen from the embodiments, the inventors succeeded in proving that cytotoxic T cells killing in an MHC-class-I-restricted manner tumor cells that create MUC-1 could be created very effectively by means of the nonapeptide. Namely, these tumor cells present, via MHC class I molecules, certain fragments of all proteins generated by them. If now cytotoxic T cells recognize the peptide presented by a MHC class I molecule, by which peptide they were originally activated, they kill this cell. Thus, this peptide that is presented by MHC class I molecules of MUC-1 expressing cells offers the advantageous possibility to trigger selectively an immune reaction against tumors which generate MUC-1.

It was particularly surprising that even with the help of a peptide having a sequence that is not located in the mature MUC-1 protein on the cell surface, but only in the signal peptide of the immature protein, cytotoxic T cells can be induced

which show an MHC-restricted cytotoxic activity against MUC-1 expressing tumor cells.

A signal peptide of the immature protein is understood to be a peptide that is coded by the gene MUC-1 and that is generated in the cell in one piece with the rest of the protein, but that is cleaved off from same in the course of the processing in the endoplasmatic reticulum of the cells.

Peptide SEQ ID NO: 2 is an example of a nonapeptide that is derived from the amino acid sequence of the signal peptide from MUC-1. This peptide results in an effective immune reaction against MUC-1 generating tumor cells. The possibility to create cytotoxic T cells which are directed against a further peptide presented by MHC-1 molecules has the advantage that the immune reaction against tumor cells can be even further increased by the simultaneous use of cytotoxic T cells which are directed against both peptides presented by MHC-1 molecules.

Moreover, via an MHC class I molecule, a signal peptide can be presented also from such MUC-1 producing tumor cells which, due to a degeneration, do not have a functioning system that transports peptides created in the cytosol of the cell into the endoplasmatic reticulum (ER) which peptides are to be presented by MHC class I molecules. In the ER, namely, the peptides are first assembled with the MHC class I molecules and only then brought onto the cell surface. Since the signal peptide is cleaved off only in the ER, for its MHC-class-I-mediated presentation no transport into the ER is necessary. Thus, an immune reaction that was triggered by the peptide with the sequence SEQ ID NO: 2 can be directed against a larger number of tumor

cells than an immune reaction that was triggered by peptides which are not derived from the MUC-1 signal peptide.

Modified forms of the peptides SEQ ID NO: 1 and/or 2 can also result in the desired immune response.

According to the invention, modified means each chemical, enzymatic or another modification of the peptide. This can be done e.g. already in the generation of the peptide or later by removing or adding individual amino acid residues, the exchange of individual amino acid residues, and also by the chemical modification of individual amino acid residues by adding certain chemical groups.

In another preferred embodiment, the invention relates to a nucleic acid which comprises a part of a sequence which codes for at least one peptide according to the invention. Furthermore, the nucleic acid may comprise further sequences which are necessary for the expression of the nucleic acid sequence corresponding to the peptide. The nucleic acid used can be contained in a vector which is suitable to allow the expression of the nucleic acid sequence corresponding to the peptide in a cell.

Such a nucleic acid has the advantage that it is chemically more stable and less sensitive than peptides. The handling, thus, is simpler than that of peptides, and the storability of nucleic acids is nearly indefinite. They can be produced cheaply by chemical and/or molecular-biological means and, in principle, can be produced in unlimited amounts. Nucleic acid sequences that may be necessary for the expression have the advantage, just like a vector that contains the nucleic acids,

that it is thereby possible to produce large amounts of peptides in a very cost effective manner in cellular expression systems by means of nucleic acids. The nucleic acids can, however, also be used for transforming antigen-presenting cells, in particular dendritic cells, such that they generate the corresponding peptides themselves, and then presenting them to cytotoxic T cells or the precursor cells of same, respectively, by means of MHC-1 molecules.

Another aspect of the invention relates to a pharmaceutical composition which comprises a peptide according to the invention or a nucleic acid according to the invention, in an amount which is sufficient for triggering an MHC-1-restricted immune response.

To this end, the peptides and/or nucleic acids may be prepared in the common galenicals which are appropriate in each case. In the case of peptides, these can e.g. be preparations which are usually used for vaccinations and which contain an adjuvans. In the case of nucleic acids, also a preparation with liposomes or vesicles is possible. By means of an appropriate pharmaceutical preparation, it is possible to treat organisms directly, without having to withdraw antigen-presenting cells or the precursor cells of same, respectively, in order to culture these for a while and to bring them into the patient after having treated them with peptides or nucleic acids. By means of a suitable pharmaceutical preparation, a tumor treatment can be effected in the form of a vaccination.

Another aspect of the invention relates to the use of a nucleic acid according to the invention within the scope of a gene therapy.

Herein, the gene therapy can be performed by transformation of antigen-presenting cells, already described above, in particular of dendritic cells, which or the precursor cells of which were withdrawn from the body of an organism to be treated, prior to be brought again into the body after the transformation. In comparison to the use of peptides, the longer lasting presentation is advantageous herein, as explained above.

Another possibility is to bring the nucleic acid in the body such that it is selectively absorbed and expressed by antigen-presenting cells, in particular by dendritic cells. This application has the advantage that, apart from the administration, no further measures are necessary, like e.g. the culture and the selective reproduction of the withdrawn dendritic cells or the precursor cells of the same.

The invention further relates to the use of a nucleic acid according to the invention for the transformation or transfection of cells in vitro. The use of the nucleic acid in vitro has the advantage that processes, like e.g. the electroporation, and/or auxiliary materials, like e.g. calcium phosphate or DEAE dextran, can be used, which considerably facilitate and improve the absorption of nucleic acids into cells, but which are not applicable in vivo.

In this process, as already mentioned, antigen-presenting cells, in particular dendritic cells or the precursor cells



antigen-presenting cells or the precursor cells of the same were withdrawn before.

The advantage of this process is that when triggering an immune reaction in this way the success is safer and more controllable than with the injection of a peptide together with an adjuvans, for which the immune reaction may happen stronger or weaker. Just for a tumor therapy, however, success for triggering an immune reaction should be made sure, so that no precious time gets lost because of an ineffective treatment.

It is to be understood that the features mentioned above and those yet to be explained below can be used not only in the respective combinations indicated, but also in other combinations or in isolation, without leaving the scope of the present invention.

Embodiments of the invention will be shown and explained in the description below.

Example 1            Induction of antigen-specific cytotoxic T cells  
                         by using peptides and dendritic cells

#### 1.1 Providing dendritic cells

As e.g. described by Brossart, P., et al., Cancer Res 58 (1998), pages 732 ff., first of all, mononuclear cells of peripheral blood were isolated from buffy coat preparations of heparinized blood of three healthy donators by Ficoll/Paque (Gibco-BRL, Grand Island, NY) density-gradient centrifugation. The cells were seeded in cell culture bowls in RP10 medium. Af-

ter two hours at 37°C, the cells that did not adhere were removed and the adhering blood monocytes were cultivated in RP10 medium that contained the following cytokine additives: human recombinant GM-CSF (Leukomax, Sandoz, 100 ng/ml), IL-4 (Genzyme, 1000 IU/ml), and TNF- $\alpha$  (Genzyme, 10 ng/ml). After seven days of cultivation, in the FACS analysis the cells showed a strong expression of the surface marker MHC class I and II, CD83, CD80, CD86, CD40 and CD54, characteristic of the phenotype of mature dendritic cells, and therefore were identified as dendritic cells.

## 1.2 Identification of suitable peptides

For identifying peptides which were presented by HLA-A2 with a high probability, first of all, the amino acid sequence coded by the gene MUC-1 was searched for potential HLA-A\*0201 (a certain HLA-A2 type) binding peptide motives by means of a computer program, as described, for example, in Rammensee, H.G., et al., Landes Bioscience, Austin, Texas, USA (1997).

The selected sequences and control sequences as well as a PAN-HLA-DR-binding peptide were synthesized on a peptide synthesizer by using standard Fmoc chemistry.

## 1.3 Induction of cytotoxic T cells

$5 \times 10^5$  dendritic cells from 1.1 were incubated with 50  $\mu$ g/ml synthetic peptide from 1.2 for two hours, washed, and incubated with  $2.5 \times 10^6$  autologous, i.e. coming from the same donors, mononuclear cells of periphery blood in RP10 medium. Additionally to the control peptides and the potentially HLA-A2 binding



peptides the dendritic cells were partly incubated with 50  $\mu\text{g/ml}$  of a PAN-HLA-DR-binding peptide which represents a T helper epitope.

After seven days of cultivation, the cells were again stimulated by adding autologous, mononuclear cells of peripheral blood pre-incubated with the synthetic peptide from 1.2. On the first, third and fifth day, respectively, 1 ng/ml human recombinant IL-2 (Genzyme) was added. The cytokine IL-2 is necessary for the cultivation and reproduction of cytotoxic T cells. Altogether, stimulation was effected up to three times in an interval of a week.

#### 1.4 Proof of cytotoxic T cell activity

T2 cells which are distinguished by the fact that they can generate HLA-A2, but cannot present peptides synthesized by themselves via this MHC class I molecules, were pre-incubated with 50  $\mu\text{g/ml}$  of synthetic peptide from 1.2 for two hours and marked with [ $^{51}\text{Cr}$ ]-sodium chromate in RP10 at 37°C for one hour. In each case  $10^4$  of these cells were transferred into each of a well of a 96-well-plate. Cytotoxic T cells that were generated before according to 1.3 were added, so that, respectively, an end volume of 200  $\mu\text{l}$  per well was reached. Subsequently, incubation took place for four hours at 37°C. If now the cytotoxic T cells kill the cells that were labeled with  $^{51}\text{Cr}$  before, they lyse these cells, and the  $^{51}\text{Cr}$  contained in the cells is released. At the end of the experiment in the cell supernatants taken off, the released radioactivity is determined by counting in a  $\beta$ -counter. In that way, a measure for the cytotoxic activity of T cells is obtained.

### 1.5 Peptides triggering a HLA-A2-restricted immune response

Two of the synthesized peptides which are derived from the sequence of the MUC-1 gene were able to induce cytotoxic T cells in vitro by means of dendritic cells in the process mentioned above. These are the two peptides with the sequence SEQ ID NO: 1 and the sequence SEQ ID NO: 2 from the sequence protocol. The cytotoxic T cells that were induced by using the peptide with the sequence SEQ ID NO: 1 were able to specifically kill T2 cells that were pre-treated with exactly this peptide, whereas they were not able to kill T2 cells that were pre-treated with other peptides. On the other hand, cytotoxic T cells which were induced by using other peptides were not able to kill T2 cells which were pre-treated with the peptide with the sequence SEQ ID NO: 1. Cytotoxic T cells which were induced by using the peptide with the sequence SEQ ID NO: 2 do behave in the same way. These cells could kill only those cells which were pre-treated with the peptide with the sequence SEQ ID NO: 2.

In this process, cytotoxic T cells which were induced in the presence of the PAN-HLA-DR-binding peptide showed a higher cytotoxic activity than those which were induced when this peptide was not present.

Example 2      Lysis of tumor cells by MUC-1 peptide specific  
cytotoxic T cells

Different tumor cell lines that express either both HLA-A2 and MUC-1 or only one of the two cell surface molecules, respectively, as proven by FACS-analysis, were labeled with <sup>51</sup>Cr, as described under 1.4 for T cells. After that, as also described under 1.4, the cells were incubated with cytotoxic T cells which were induced as described under 1.3.

Those T cells that were activated by using the peptides with the sequence SEQ ID NO: 1 or the sequence SEQ ID NO: 2 were able to lyse tumor cells of the lines MCF-7 (breast cancer cells), A-498 (kidney cell carcinoma cells) and MZ1774-RCC (kidney cell carcinoma cells) which express HLA-A2 and MUC-1. However, they were not able to lyse cells of the cell lines Croft (EBV immortalized B cells) which do not express MUC-1, as well as Caki-2 (kidney cell carcinoma cells), SK-OV-3 (ovary cancer cells) and K562 (pro-erythroblastic cells) which do not express HLA-A2.

The cytotoxic T cells that were activated by using the peptides with the sequence SEQ ID NO: 1 and SEQ ID NO: 2 could neither lyse the kidney cell carcinoma cells of the line MZ1774-RCC expressing HLA-A2 and MUC-1, if the kidney cell carcinoma cells were incubated before with 10 µg/ml of a monoclonal antibody (BB7.2, Coulter-Immunotech) directed against HLA-A2 for 30 minutes.

These results show that the cytotoxic T cells generated by using the peptides according to the invention kill only tumor cells which express both HLA-A2 and MUC-1.

Thus, the peptides according to the invention are suitable for triggering an immune reaction against certain tumor cells also within the scope of a therapy.

First studies in which such a therapy was used for patients suffering from breast cancer and in which the patients have responded to the immune therapy will soon be finished.

## SEQUENCE LISTING

<110> Eberhard-Karls-Universitaet Tuebingen

<120> Peptide for triggering an immune reaction against  
tumor cells

<130> 5402P168

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

<213> Artificial sequence

<220>

<223> Description of the artificial sequence: fragment  
from human protein coded by the gene MUC-1

<400> 1

Ser Thr Ala Pro Pro Val His Asn Val

<210> 2

<211> 9

<212> PRT

<213> Artificial sequence

$\langle 220 \rangle$

<223> Description of the artificial sequence: fragment  
from human protein coded by the gene MUC-1

<400> 2

Leu Leu Leu Leu Thr Val Leu Thr Val

1

5

Claims

1. A peptide that is derived from the MUC-1 gene and by which a HLA-A2-restricted immune reaction against tumor cells can be triggered, characterized in that it comprises the sequence SEQ ID NO: 1:

Ser Thr Ala Pro Pro Val His Asn Val,

and/or a sequence that is derived from the signal peptide, in particular the sequence SEQ ID NO: 2:

Leu Leu Leu Leu Thr Val Leu Thr Val,

and/or

a modified form of the sequence SEQ ID NO: 1 and/or of the sequence SEQ ID NO: 2.

2. A nucleic acid which comprises a part of a sequence which codes for a peptide according to claim 1.
3. The nucleic acid of claim 2, characterized in that the nucleic acid comprises sequences which are necessary for the expression of the nucleic acid sequence corresponding to the peptide.
4. The nucleic acid of claim 2 or 3, characterized in that the nucleic acid is contained in a vector which is suit-

able to allow the expression in a cell of the nucleic acid sequence corresponding to the peptide.

5. A pharmaceutical composition, characterized in that it comprises a peptide and/or a nucleic acid of one of claims 1 through 4 in an amount which is sufficient for triggering an MHC-1-restricted immune response.
6. Use of a nucleic acid of one of claims 3 through 5 within the scope of a gene therapy.
7. Use of a nucleic acid of one of claims 3 through 5 for the transformation or transfection of cells in vitro.
8. Use of at least one peptide or one nucleic acid of one or several of claims 1 through 4 for triggering an immune reaction in connection with a tumor therapy or with a prophylactic treatment with respect to the development of a tumor.
9. Use of at least one of the peptides or of a nucleic acid of one or several of claims 1 through 4 in combination with a Pan-HLA-DR-binding peptide.
10. The use of claim 8 or 9, characterized in that at least one of the peptides or one of the nucleic acids is incubated together with antigen-presenting cells, in particular with dendritic cells, and only then is brought into an organism from which the antigen-presenting cells or the precursor cells of the same were withdrawn before.



PCT

WELTORGANISATION FÜR GEISTIGES EIGENTUM  
Internationales Büro

INTERNATIONALE ANMELDUNG VERÖFFENTLICHT NACH DEM VERTRAG ÜBER DIE  
INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT)

10019513



1602

(51) Internationale Patentklassifikation <sup>7</sup> : C12N 15/11, C07K 14/47, A61K 48/00		A1	(11) Internationale Veröffentlichungsnummer: WO 00/63363
		(43) Internationales Veröffentlichungsdatum:	26. Oktober 2000 (26.10.00)
(21) Internationales Aktenzeichen: PCT/EP00/02699		(81) Bestimmungsstaaten: AU, CA, JP, US, europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) Internationales Anmeldedatum: 28. März 2000 (28.03.00)			
(30) Prioritätsdaten: 199 17 195.5 16. April 1999 (16.04.99) DE		Veröffentlicht <i>Mit internationalem Recherchenbericht. Vor Ablauf der für Änderungen der Ansprüche zugelassenen Frist; Veröffentlichung wird wiederholt falls Änderungen eintreffen.</i>	
(71) Anmelder (für alle Bestimmungsstaaten ausser US): EBER- HARD-KARLS-UNIVERSITÄT TÜBINGEN UNIVER- SITÄTSKLINIKUM [DE/DE]; Geissweg 3, D-72076 Tübingen (DE).			
(72) Erfinder; und			
(75) Erfinder/Anmelder (nur für US): KANZ, Lothar [DE/DE]; Im Schönblick 24, D-72076 Tübingen (DE). RAMMENSEE, Hans, Georg [DE/DE]; Sommerhalde 3, D-72070 Tübingen-Unterjesingen (DE). BRUGGER, Wolfram [DE/DE]; Birsmarckstrasse 57/1, D-72127 Kusterdingen (DE). STEVANOVIC, Stefan [DE/DE]; Auf der Burg 3, D-72074 Tübingen (DE). BROSSART, Peter [DE/DE]; Laura-Schradin-Weg 23, D-72762 Reutlingen (DE).			
(74) Anwälte: OTTEN, Hajo usw.; Witte, Weller & Partner, Postfach 105462, D-70047 Stuttgart (DE).			
(54) Title: PEPTIDE FROM ANTIGEN MUC-1 FOR TRIGGERING AN IMMUNE RESPONSE TO TUMOR CELLS			
(54) Bezeichnung: PEPTID AUS ANTIGEN MUC-1 ZUR AUSLÖSUNG EINER IMMUNREAKTION GEGEN TUMORZELLEN			
(57) Abstract			
The invention relates to a peptide for triggering an immune response to tumor cells. Said peptide has an optionally modified fragment of the protein that is encoded by the gene MUC-1. Said protein triggers an HLA-A2-restricted immune response.			
(57) Zusammenfassung			
Es wird ein Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen bereitgestellt, das ein ggf. modifiziertes Fragment des durch das Gen MUC-1 codierten Proteines aufweist, das eine HLA-A2-restringierte Immunreaktion auslösen kann.			



5402P/168 US

Page 1

Attorney's Docket No. WWELL52.001APC

**DECLARATION - USA PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled PEPTIDE FOR TRIGGERING AN IMMUNE REACTION AGAINST TUMOR CELLS; the specification of which was internationally filed on March 28, 2000, as International Application No. PCT/EP00/02699, and for which the initial documents for entry into the U.S. National Phase were mailed on October 16, 2001 as Application Serial No. 10/019,513.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above;

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56;

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

**PRIOR FOREIGN APPLICATIONS****Priority  
Claimed**

No.: PCT/EP00/02699	Country: Germany	Date Filed: March 28, 2000	Yes
No.: 19917195.5	Country: Germany	Date Filed: April 16, 1999	Yes

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Page 3

Attorney's Docket No. WWELL52.001APC

4-00

Full name of fourth inventor: Lothar KanzInventor's signature X [Signature]Date X July 23, 2002Residence: Im Schonblick 24, D-72076 Tübingen GERMANY DEX

Citizenship: German

Post Office Address: Same As Above

5-00

Full name of fifth inventor: Hans Georg RammenseeInventor's signature X [Signature]Date X July 24, 2002Residence: Sommerhalde 3, D-72070 Tübingen-Unterjessingen GERMANY DEX

Citizenship: German

Post Office Address: Same As Above

Send Correspondence To:  
KNOBBE, MARTENS, OLSON & BEAR, LLP  
Customer No. 20,995

H:\DOCS\CMS\CMS-2720.DOC\dms  
061602

Page 2

Attorney's Docket No. WWELL52.001APC

(-00

Full name of first inventor: Peter Brossart

Inventor's signature *Peter Brossart*

Date *29.07.02*

Residence: Laura-Schradin-Weg 23, D-72762 Reutlingen GERMANY

DEX

Citizenship: German

Post Office Address: Same As Above

2-00

Full name of second inventor: Stefan Stevanovic

Inventor's signature *Stefan Stevanovic*

Date *24.07.2002*

Residence: Auf der Brug 3, D-72074 Tübingen Germany

DEX

Citizenship: German

Post Office Address: Same As Above

3-00

Full name of third inventor: Wolfram Brugger

Inventor's signature *Wolfram Brugger*

Date *July 31, 2002*

Residence: Bismarckstr. 57/1, D-72127 Kusterdingen GERMANY

Citizenship: German

Post Office Address: Same As Above



PCT10

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/10/019,513

DATE: 01/22/2002  
TIME: 10:43:42

Input Set : A:\WWELL52.001APC.TXT  
Output Set: N:\CRF3\01182002\J019513.raw

**ENTERED**

4 <110> APPLICANT: Brossart, Peter  
5 Stevanovic, Stefan  
6 Brugger, Wolfram  
7 Kanz, Lothar  
8 Rammensee, Hans Georg  
11 <120> TITLE OF INVENTION: PEPTIDE FOR TRIGGERING AN IMMUNE  
12 REACTION AGAINCT TUMOR CELLS  
15 <130> FILE REFERENCE: WWELL52.001APC  
17 <140> CURRENT APPLICATION NUMBER: US/10/019,513  
18 <141> CURRENT FILING DATE: 2001-10-16  
20 <150> PRIOR APPLICATION NUMBER: DE 19917195.5  
21 <151> PRIOR FILING DATE: 1999-04-16  
23 <160> NUMBER OF SEQ ID NOS: 2  
25 <170> SOFTWARE: FastSEQ for Windows Version 4.0  
27 <210> SEQ ID NO: 1  
28 <211> LENGTH: 9  
29 <212> TYPE: PRT  
30 <213> ORGANISM: Artificial Sequence  
32 <220> FEATURE:  
33 <223> OTHER INFORMATION: Fragment of human protein encoded by the gene  
34 MUC-1  
36 <400> SEQUENCE: 1  
37 Ser Thr Ala Pro Pro Val His Asn Val  
38 1 5  
41 <210> SEQ ID NO: 2  
42 <211> LENGTH: 9  
43 <212> TYPE: PRT  
44 <213> ORGANISM: Artificial Sequence  
46 <220> FEATURE:  
47 <223> OTHER INFORMATION: Fragment of human protein encoded by the gene  
48 MUC-1  
50 <400> SEQUENCE: 2  
51 Leu Leu Leu Leu Thr Val Leu Thr Val  
52 1 5

VERIFICATION SUMMARY

DATE: 01/22/2002

PATENT APPLICATION: US/10/019,513


TIME: 10:43:43

Input Set : A:\WWELL52.001APC.TXT

Output Set: N:\CRF3\01182002\J019513.raw

L:17 M:270 C: Current Application Number differs, Replaced Current Application Number

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☒ Page(s) 30 of 3 of Sequence <sup>was</sup> ~~were~~ not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not  
present  
for scanning. (Document title)

☐ *Scanned copy is best available.*